Diagnosis and Treatment of Acne

American Family Physician

Volumn 69, Issue 9, 2004, Pages 2123-2130+2135

  Feldman, Steven ^a   Careccia, Rachel E ^a   Barham, Kelly L ^a,b   Hancox, John ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b MOSES H CONE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; AMNESTEEM; ANABOLIC AGENT; AZATHIOPRINE; AZELAIC ACID; BENZOYL PEROXIDE; BROMIDE; CLINDAMYCIN; CORTICOSTEROID; CORTICOTROPIN; CYCLOSPORIN; CYCLOSPORIN A; DANAZOL; DISULFIRAM; DOXYCYCLINE; ERYTHROMYCIN; ERYTHROMYCIN STEARATE; HP ACTHAR; ISONIAZID; ISOTRETINOIN; KLARON; LITHIUM; MINOCYCLINE; NORETHISTERONE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; ORTHOCYCLEN; PHENOBARBITAL; PHENYTOIN; PREDNISONE; QUINIDINE; RETIN A MICRO; RETINOIC ACID; RETINOID; SULFACET R; SULFACETAMIDE; TAZAROTENE; TESTOSTERONE; TETRACYCLINE; UNINDEXED DRUG; ZOVIA;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE; ANOREXIA; ANXIETY; ARTHRALGIA; ATAXIA; BIRTH DEFECT; BRAIN PSEUDOTUMOR; CATARACT; CHEILITIS; COMEDO; CONJUNCTIVITIS; CONTACT DERMATITIS; CORNEA OPACITY; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG COST; DRUG HYPERSENSITIVITY; DRY SKIN; DYSPEPSIA; EOSINOPHILIA; EPISTAXIS; ERYTHEMA; ESOPHAGITIS; GENERAL PRACTITIONER; HEADACHE; HUMAN; HYPEROSTOSIS; HYPERTRIGLYCERIDEMIA; HYPOPIGMENTATION; JAUNDICE; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; MELENA; NAUSEA; NEUTROPENIA; PATIENT EDUCATION; PHOTOSENSITIVITY; PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN ABRASION; SKIN BURNING SENSATION; SKIN IRRITATION; STOMATITIS; TERATOGENICITY; THROMBOCYTOPENIA; TINNITUS; TOOTH COLOR; TREATMENT OUTCOME; VERTIGO; VISUAL IMPAIRMENT; VOMITING;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; CONTRACEPTIVES, ORAL; HUMANS; RETINOIDS;

EID: 2342605457     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Gollnick HP, Zouboulis CC, Akamatsu H, Kurokawa I, Schulte A. Pathogenesis and pathogenesis related treatment of acne. J Dermatol 1991;18:489-99.
2. Holmes RL, Williams M, Cunliffe WJ. Pilo-sebaceous duct obstruction and acne. Br J Dermatol 1972;87:327-32.
3. White GM. Acne therapy. Adv Dermatol 1999;14:29-59.
4. Zaenglein AL, Thiboutot DM. Acne vulgaris. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. New York: Mosby, 2003:533-4.
5. Mengesha YM, Bennett ML. Pustular skin disorders: diagnosis and treatment. Am J Clin Dermatol 2002;3:389-400.
6. Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol 2003;4:315-31.
7. Pochi PE, Shalita AR, Strauss JS, Webster SB, Cunliffe WJ, Katz HI, et al. Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990. J Am Acad Dermatol 1991;24:495-500.
8. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology 1998;196:119-25.
9. Millikan LE. The rationale for using a topical retinoid for inflammatory acne. Am J Clin Dermatol 2003;4:75-80.
10. Embil K, Nacht S. The microsponge delivery system (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul 1996;13:575-88.
11. Van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol 1998;11(suppl 1):S13-9.
12. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998;139(suppl 52):48-56.
13. Thiboutot D, Gold MH, Jarratt MT, Kang S, Kaplan DL, Millikan L, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001;68(4 suppl):10-9.
14. Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis 2001;67(6 suppl):4-9.
15. Leyden JJ, Tanghetti EA, Miller B, Ung M, Berson D, Lee J. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis 2002;69(2 suppl):12-9.
16. Liao DC. Management of acne. J Fam Pract 2003;52:43-51.
17. Leyden JJ, Hickman JG, Jarratt MT, Stewart DM, Levy SF. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001;5:37-42.
18. Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002;24:1117-33.
19. Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther 1998;20:945-59.
20. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003;206:54-6.
21. Garner SE, Eady EA, Popescu C, Newton J, Li Wan Po A. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2003;(1): CD002086.
22. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997;133:1224-30.
23. Tan HH. Antibacterial therapy for acne: a guide to selection and use of systemic agents. Am J Clin Dermatol 2003;4:307-14.
24. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002;46:917-23.
25. Shaw JC. Acne: effect of hormones on pathogenesis and management. Am J Clin Dermatol 2002;3:571-8.
26. Lowenstein EJ. Isotretinoin made S.M.A.R.T. and simple. Cutis 2002;70:115-20.
27. Ellis CN, Krach, KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001;45:S150-7.
28. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000;136:1231-6.
29. Katsambas AD. Why and when the treatment of acne fails. What to do. Dermatology 1998;196:158-61.
30. Jordan RE, Cummins CL, Burls AJ, Seukeran DC. Laser resurfacing for facial acne scars. Cochrane Database Syst Rev 2004;(1):CD001866.
31. Goodman G. Post acne scarring: a review. J Cosmet Laser Ther 2003;5:77-95.